Protocol
Intermittent hypoxic-hyperoxic training (IHHT)
IHHT · Intermittent hypoxia hyperoxia therapy · ReOxy · Intermittent hypoxic-hyperoxic therapy · Altitude training at sea level · Hypoxic training · Interval hypoxic training
There is genuine human controlled data, but not for longevity. The strongest available study (Bahenský et al. context aside, the key trial is the German long COVID study, PMC11634465) was a prospective, controlled, OPEN-TREATMENT, NON-RANDOMISED pilot in 145 inpatients at a single German rehabilitation centre. The IHHT arm (n=70) improved 6-minute walk distance 2.8-fold more than standard care (91.7 m vs 32.6 m, p<0.001), with secondary gains in stair-climbing power, dyspnoea, fatigue, quality of life and handgrip. The authors themselves state the design had limited strength due to absence of blinding and non-random assignment, producing baseline imbalance between groups. So: this is deconditioned post-viral patients regaining function during a five-week inpatient rehab programme, not healthy adults gaining healthspan. What the evidence does NOT show: any effect on mortality, biological age, epigenetic clocks, or any longevity or healthspan endpoint; any benefit in healthy or asymptomatic people; any durability beyond the treatment window. The mitochondrial-rejuvenation and anti-ageing claims made in clinic marketing are mechanistic extrapolation, not demonstrated outcomes. Safety signals appear benign in supervised use, though the "no reported adverse events" claim cited by at least one Australian provider rests on an unpublished 2015 literature review, which is not verifiable evidence. Note also that provision in Australia sits mainly with naturopathic and wellness practices rather than medical longevity clinics, which is itself informative about how the intervention is positioned.
At a glance
- Evidence
- Commercial
- Singapore (HSA)
- No HSA position on file
- Australia (TGA)
- NOT INDEPENDENTLY VERIFIED - treat as a distributor claim, not as established fact. The Australian ReOxy distributor states on its own site, verbatim: "ReOxy device is entered in the Australian Register of Therapeutic Goods (ARTG 408421)". I was unable to confirm this against the TGA's own register: tga.gov.au/resources/artg/408421 timed out on repeated attempts and the ARTG search interface was unreachable in this session, so the sponsor, device class and, critically, the registered intended purpose remain unconfirmed. An ARTG entry, if it exists, would establish only that the device may lawfully be supplied in Australia for its registered intended purpose; it would NOT constitute TGA endorsement of anti-ageing, longevity or healthspan claims. Separately, none of the Australian provider pages reviewed (Tsavo Wellness, The Orchard, Rosalba Courtney) make any TGA or ARTG claim at all, and The Orchard positions ReOxy explicitly as a wellness service rather than a medical treatment. BEFORE PUBLICATION: the ARTG number 408421 must be checked directly against the TGA register and the registered intended purpose quoted.
- Offered at
- No clinic on file
Singapore
Health Sciences Authority
- HSA status
- No position on file
- In our SG set
- Not tracked in Singapore
- SG clinics
- None on file
Australia
Therapeutic Goods Administration
- TGA status
- NOT INDEPENDENTLY VERIFIED - treat as a distributor claim, not as established fact. The Australian ReOxy distributor states on its own site, verbatim: "ReOxy device is entered in the Australian Register of Therapeutic Goods (ARTG 408421)". I was unable to confirm this against the TGA's own register: tga.gov.au/resources/artg/408421 timed out on repeated attempts and the ARTG search interface was unreachable in this session, so the sponsor, device class and, critically, the registered intended purpose remain unconfirmed. An ARTG entry, if it exists, would establish only that the device may lawfully be supplied in Australia for its registered intended purpose; it would NOT constitute TGA endorsement of anti-ageing, longevity or healthspan claims. Separately, none of the Australian provider pages reviewed (Tsavo Wellness, The Orchard, Rosalba Courtney) make any TGA or ARTG claim at all, and The Orchard positions ReOxy explicitly as a wellness service rather than a medical treatment. BEFORE PUBLICATION: the ARTG number 408421 must be checked directly against the TGA register and the registered intended purpose quoted.
- In our AU set
- Tracked in Australia
- AU clinics
- None on file
What it is
Plain-language explainer
IHHT is a breathing protocol in which a person alternates, through a mask, between inhaling low-oxygen air (roughly 10 to 12 percent O2, simulating altitude) and oxygen-enriched air (roughly 30 to 35 percent O2), in cycles over a 30 to 60 minute passive session. In Australia it is delivered almost entirely via the ReOxy device, developed in Luxembourg and manufactured in Germany, which adjusts the hypoxic dose to the individual's measured response. Providers claim it improves mitochondrial function, cellular energy metabolism, endurance, stress resilience, sleep, cognition and fat metabolism; the longevity framing is built on the mitochondrial and hormesis story rather than on longevity outcome data.
Categories
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- ReOxy Australia - official Australian distributor site · ReOxy Australia
- IHHT - ReOxy Australia (source of the ARTG 408421 claim) · ReOxy Australia
- Intermittent hypoxic-hyperoxic training in long COVID inpatient rehabilitation: prospective controlled open-treatment pilot study · PubMed Central (PMC11634465)
- ReOxy Intermittent Hypoxia Therapy · Tsavo Wellness and Recovery Centre, Mosman NSW
- ReOxy Breathing Therapy - exclusive Melbourne wellness provider claim · The Orchard Wellness, Prahran and Richmond VIC
- IHHT - Dr Rosalba Courtney, Avalon and Edgecliff clinics · Rosalba Courtney
Every entity profile on variis is sourced. Not medical advice.